导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.47% | 736/1840 |
| 近一周 | -2.23% | 1291/2029 |
| 近一月 | -6.22% | 1430/2018 |
| 近一季 | -10.72% | 1383/1966 |
| 近半年 | -3.09% | 885/1877 |
| 近一年 | 4.87% | 651/1753 |
| 近两年 | 65.49% | 431/1324 |
| 近三年 | 32.93% | 384/1010 |
| 成立以来 | 207.22% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.18% 2164/4961 |
19.74% 1279/5312 |
- - |
- - |
| 2025 | 30.19% 1344/4813 |
0.81% 1765/3635 |
-0.67% 2996/4076 |
30.96% 1148/4524 |
-0.73% 2621/4813 |
| 2024 | 7.47% 1653/3463 |
-0.98% 1159/2808 |
-3.59% 1396/3014 |
14.67% 1933/3129 |
-1.83% 1853/3463 |
| 2023 | -16.72% 1696/2656 |
2.32% 1378/2280 |
-4.74% 1271/2385 |
-9.02% 1767/2515 |
-6.09% 1625/2655 |
| 2022 | -23.74% 1163/2207 |
-18.41% 1333/1919 |
7.37% 487/2016 |
-14.97% 1180/2113 |
2.37% 957/2208 |
| 2021 | 12.84% 374/1822 |
-4.50% 870/1255 |
17.54% 187/1330 |
-3.91% 666/1466 |
4.62% 323/1822 |
| 2020 | 53.80% 146/1250 |
-3.01% 286/1028 |
24.34% 172/1067 |
10.73% 517/1164 |
15.17% 229/1184 |
| 2019 | 50.21% 101/1092 |
35.55% 93/754 |
-3.65% 404/804 |
4.50% 199/850 |
10.06% 168/918 |
| 2018 | -33.43% 552/834 |
- - |
- - |
- - |
-12.53% 453/691 |
| 2017 | 20.19% 187/714 |
- - |
- - |
- - |
- - |
| 2016 | -15.01% 346/605 |
- - |
- - |
- - |
- - |
| 2015 | 34.45% 61/575 |
- - |
- - |
- - |
- - |
| 2014 | 30.12% 164/237 |
- - |
- - |
- - |
- - |
| 2013 | 5.34% 52/186 |
- - |
- - |
- - |
- - |
| 2012 | 0.73% 111/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 平安深证300指数增强 VS. 长安沪深300非周期A(740101) |